A pharmaceutical composition comprising extract of Lilium brownii var. viridulum Baker for prevention and treatment of Sjogren's syndrome

A lily extract-based composition addresses the limitations of current Sjögren's syndrome treatments by increasing AQP5 expression, reducing inflammatory cytokines, and decreasing autoantibodies, offering a potential cure without side effects.

KR103042620B1Active Publication Date: 2026-11-06UNIVERSITY INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020230118835
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-09-07
Publication Date
2026-11-06
Estimated Expiration
2043-09-07

AI Technical Summary

Technical Problem

Current treatments for Sjögren's syndrome, such as artificial tears and immunosuppressants, provide only temporary relief and have side effects, while the exact cause and pathological mechanisms of the disease remain unknown, necessitating a need for a drug without side effects for fundamental cure.

Method used

A pharmaceutical and food composition containing lily extract as an active ingredient, which increases Aquaporin-5 (AQP5) expression, reduces inflammatory cytokines TNF-α, IFN-γ, and IL-6 secretion, and decreases autoantibodies anti-SSA/Ro and anti-SSB/La production, prepared by drying lilies, extracting with distilled water, concentrating, and freeze-drying.

Benefits of technology

The lily extract composition effectively increases saliva secretion, reduces inflammation, and protects salivary glands, providing a potential cure for Sjögren's syndrome without side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023098883117-PAT00001_ABST
    Figure 112023098883117-PAT00001_ABST
Patent Text Reader

Abstract

The present invention confirms that a lily extract has the effect of increasing the expression of Aquaporin-5 (AQP5) and muscarinic acetylcholine receptor (M3R), decreasing the production of autoantibodies anti-SSA / Ro and anti-SSB / La, and decreasing the secretion of inflammatory cytokines TNF-α, IFN-γ, or IL-6, and provides a pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome comprising the lily extract as an active ingredient.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome comprising lily extract as an active ingredient. Background Technology

[0003] Sjogren's syndrome is a chronic and systemic autoimmune disease caused by the infiltration of lymphocytes and autoimmune antibodies into exocrine glands, such as salivary and lacrimal glands. Dry eyes and xerostomia result from inflammation and destruction of the salivary and lacrimal glands. Xerostomia can cause dysphagia, difficulty chewing, difficulty speaking, changes in taste, increased tooth decay, and severe physical, functional, social, and psychological effects. Although Sjogren's syndrome is the most common autoimmune disease with a prevalence of 0.5% to 1.0%, its exact cause and pathological mechanisms remain largely unknown.

[0004] Treatment for Sjögren's syndrome primarily involves alleviating dryness symptoms using artificial tears, topical lubricants (artificial saliva and vaginal lubricants), and stimulants such as pilocarpine, cevimeline, prednisone, and immunosuppressants (azathioprine, cyclosporine). However, these treatments have limitations, as long-term administration can cause side effects such as sweating, frequent urination, flushing, sinusitis, and nausea, and the symptom relief is only temporary. Therefore, there is a need to develop drugs for a fundamental cure without side effects.

[0005] The lily (*Lilium longiflorum*) is a perennial herb belonging to the genus *Lilium* of the family *Liliaceae*; commonly known as *Baekhap*, it grows to a height of approximately 30 to 100 cm. Lilies are broadly classified into flowers, leaves, stems, and bulbs, and are widely used for ornamental purposes. The main distribution areas of lilies include temperate, tropical, and mountainous regions. Lilies are diverse in type, with reports indicating that over 130 species are distributed in the temperate regions of the Northern Hemisphere, about 70 species in Asia, about 30 species in North America, about 10 species in Europe, and more than 10 varieties across the Eurasian continent. Regarding the main components of the lily, the bulb consists of water (67%), carbohydrates (27%), protein (3.7%), and fat; additionally, it contains minerals, vitamins (B1, B2, C), carotene, phosphorus (0.07%), and calcium (0.01%).

[0006] Regarding studies on the general components of the lily, research on alkaloids and steroidal saponins has been reported, and polysaccharides have been reported to inhibit melanoma (melanoma B16) and lung cancer. Some studies have also been reported on mitogenic and antifungal activities, as well as the inhibition of lipid peroxidation (anti-aging and antioxidant effects). In traditional Korean medicine, the lily is described in texts such as the *Bencao Jingyao*, *Shen Nong Ben Cao Jing*, and *Jingui Yaolue* as having a sweet taste and neutral nature; it is said to protect Qi and blood, moisturize the lungs, and be effective against edema, chronic sores, obesity, chills and fever, and general headaches.

[0007] Although research results regarding the aforementioned lily extract as a functional cosmetic ingredient have been reported, research on its pharmacological action and mechanism has been insufficient.

[0008] Accordingly, the inventors have confirmed that lily extract has the effect of increasing the expression of aquaporin-5 (AQP5) and muscarinic acetylcholine receptor (M3R), decreasing the production of autoantibodies anti-SSA / Ro and anti-SSB / La, and decreasing the secretion of inflammatory cytokines TNF-α, IFN-γ, or IL-6, and provide a pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome comprising lily extract as an active ingredient.

[0009] delete Prior art literature

[65535] Korean Published Patent 10-2010-0137223 The problem to be solved

[0010] The technical problem that the present invention aims to solve is to provide a pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome containing lily extract as an active ingredient.

[0011] The technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned technical problems will be clearly understood by those skilled in the art to which the present invention belongs from the description below. means of solving the problem

[0012] To achieve the above technical problem, one embodiment of the present invention provides a pharmaceutical composition for preventing, improving, or treating Sjögren's syndrome comprising lily extract as an active ingredient.

[0013] In an embodiment of the present invention, the extract may increase saliva secretion by increasing the expression amount of aquaporin-5 (AQP5).

[0014] In one embodiment, the extract may be characterized by reducing the secretion of inflammatory cytokines such as TNF-α, IFN-γ, or IL-6.

[0015] In one embodiment, the extract may be characterized by reducing the production of autoantibodies anti-SSA / Ro and anti-SSB / La.

[0016] In one embodiment, the extract may be characterized by increasing the expression of the muscarinic acetylcholine receptor (M3 muscarinic acetylcholine receptor; M3R).

[0017] To achieve the above technical problem, in another embodiment of the present invention, a step of drying lilies;

[0018] A step of mixing distilled water with the dried lily above in a weight ratio of 1:20 and extracting at 90 to 110 ℃ for 100 to 140 minutes;

[0019] The step of concentrating the above-mentioned extracted lily extract under reduced pressure and then filtering; and

[0020] A method for preparing a pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome is provided, comprising the step of freeze-drying the filtered extract above.

[0021] To achieve the above technical problem, another embodiment of the present invention provides a food composition for preventing or improving Sjögren's syndrome comprising lily extract as an active ingredient.

[0022] In one embodiment, the extract may increase saliva secretion by increasing the expression amount of aquaporin-5 (AQP5).

[0023] In one embodiment, the extract may be characterized by reducing the secretion of inflammatory cytokines such as TNF-α, IFN-γ, or IL-6.

[0024] In one embodiment, the extract may be characterized by reducing the production of autoantibodies anti-SSA / Ro and anti-SSB / La.

[0025] In one embodiment, the extract may be characterized by increasing the expression of the muscarinic acetylcholine receptor (M3 muscarinic acetylcholine receptor; M3R).

[0026] To achieve the above technical problem, in another embodiment of the present invention, a step of drying lilies;

[0027] A step of mixing distilled water with the dried lily above in a weight ratio of 1:20 and extracting at 90 to 110 ℃ for 100 to 140 minutes;

[0028] The step of concentrating the above-mentioned extracted lily extract under reduced pressure and then filtering; and

[0029] A method for preparing a food composition for preventing or improving Sjögren's syndrome is provided, comprising the step of freeze-drying the filtered extract above. Effects of the invention

[0031] The present invention has confirmed the effect of lily extract in increasing the expression of Aquaporin-5 (AQP5) and muscarinic acetylcholine receptor (M3R), decreasing the production of autoantibodies anti-SSA / Ro and anti-SSB / La, and decreasing the secretion of inflammatory cytokines TNF-α, IFN-γ, or IL-6, and can provide a pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome comprising lily extract as an active ingredient.

[0032] The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the composition of the invention described in the description or claims of the present invention. Brief explanation of the drawing

[0034] Figure 1 is a graph showing the change in cell viability of pyriform cells treated with lily extract. Figure 2 is a graph showing the change in salivary secretion of salivary cells by treatment with lily extract. Figure 3 shows the results of Western blot analysis of changes in aquaporin-5 (AQP5) protein expression in agar cells treated with lily extract. Figure 4 shows the results of immunofluorescence analysis of aquaporin-5 (AQP5) protein in acinar cells treated with lily extract and 2 μM / mL of 5-Aza, where A and B are the normal group, C and D are the control group, and E and F are the group treated with 100 μg / mL of LB and 5-Aza. Figure 5 shows the changes in salivary secretion of NOD / SCID mice salivary glands following treatment with lily extract. Figure 6 shows the results of western blot analysis of AQP5 and M3R proteins in the salivary glands of NOD / SCID mice treated with lily extract. Figure 7 shows the levels of autoantibodies in NOD / SCID mouse serum in the control and treatment groups confirmed by ELISA. Figure 8 shows the levels of TNF-α, IFN-γ, and IL-6 in NOD / SCID mouse serum treated with lily extract, measured by ELISA. Figure 9 shows histological changes in the salivary glands of mice, where A is the normal group (BALB / c mice), B is the control group (NOD / SCID mice), C is the lily extract 100 mg / kg treatment group, D is the lily extract 500 mg / kg treatment group, and E is the lily extract 1000 mg / kg treatment group. Specific details for implementing the invention

[0035] The present invention will be described in detail below.

[0037] The present invention relates to a pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome comprising lily extract as an active ingredient.

[0038] The pharmaceutical composition of the invention may further comprise a pharmaceutically acceptable carrier. In the present invention, the term "pharmaceutically acceptable" means exhibiting properties that are non-toxic to cells or humans exposed to the composition. The carrier may be used without limitation as long as it is known in the art, such as buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, bases, excipients, lubricants, etc.

[0039] In addition, the pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, as well as external preparations, suppositories, and sterile injectable solutions, according to conventional methods. Furthermore, it may be used in the form of external skin preparations such as ointments, lotions, sprays, patches, creams, powders, suspensions, gels, or gels. Carriers, excipients, and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulating, the composition is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

[0040] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "administration" in the present invention means introducing a specific substance into an individual by an appropriate method, and the route of administration of said composition may be any general route as long as it can reach the target tissue. It may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, topically, intranasally, intrapulmonaryly, or rectally, but is not limited thereto.

[0041] The above extract can increase saliva secretion by increasing the expression of Aquaporin-5 (AQP5).

[0042] The above extract can reduce the secretion of inflammatory cytokines such as TNF-α, IFN-γ, or IL-6.

[0043] The above extract can reduce the production of autoantibodies anti-SSA / Ro and anti-SSB / La.

[0044] The above extract can increase the expression of the muscarinic acetylcholine receptor (M3 muscarinic acetylcholine receptor; M3R).

[0045] The present invention comprises the step of drying lilies;

[0046] A step of mixing distilled water with the dried lily above in a weight ratio of 1:20 and extracting at 90 to 110 ℃ for 100 to 140 minutes;

[0047] The step of concentrating the above-mentioned extracted lily extract under reduced pressure and then filtering; and

[0048] A method for preparing a pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome may be provided, comprising the step of freeze-drying the filtered extract above.

[0049] The extract according to the present invention may be obtained by extracting and separating from nature using extraction and separation methods known in the art, and the "extract" defined in the present invention is extracted from *Lilii Bulbus* using a suitable solvent, and includes, for example, crude extracts of *Lilii Bulbus*, extracts soluble in polar solvents, or extracts soluble in non-polar solvents.

[0050] For example, the lily extract included in the composition of the present invention can be prepared in a powder state by additional processes such as vacuum distillation and freeze-drying or spray-drying, using a primary extract obtained by the above-mentioned hot water extraction or solvent extraction method.

[0051] In addition, the above primary extract may be further purified by using various chromatography methods such as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography to obtain additionally purified fractions.

[0052] In addition, the present invention provides a food composition for preventing or improving Sjögren's syndrome comprising lily extract as an active ingredient.

[0053] The above extract can increase saliva secretion by increasing the expression of Aquaporin-5 (AQP5).

[0054] The above extract can reduce the secretion of inflammatory cytokines such as TNF-α, IFN-γ, or IL-6.

[0055] The above extract can reduce the production of autoantibodies anti-SSA / Ro and anti-SSB / La.

[0056] The above extract can increase the expression of the muscarinic acetylcholine receptor (M3 muscarinic acetylcholine receptor; M3R).

[0057] The present invention comprises the step of drying lilies;

[0058] A step of mixing distilled water with the dried lily above in a weight ratio of 1:20 and extracting at 90 to 110 ℃ for 100 to 140 minutes;

[0059] The step of concentrating the above-mentioned extracted lily extract under reduced pressure and then filtering; and

[0060] A method for preparing a food composition for preventing or improving Sjögren's syndrome may be provided, comprising the step of freeze-drying the filtered extract above.

[0061] There are no restrictions on the types of food in which the composition of the present invention can be used. In addition, the composition of the present invention may be prepared by mixing other suitable auxiliary ingredients that may be included in food and known additives, depending on the choice of a person skilled in the art. Examples of foods to which it can be added include meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and it may be prepared by adding it to juices, teas, jellies, and juices prepared using the extract and fractions thereof according to the present invention as main ingredients.

[0063] Hereinafter, in order to specifically explain the present invention, it will be described in detail with reference to examples.

[0065] <Experimental Example>

[0066] 1. Lily extract preparation

[0067] 50 g of dried lily bulbus sample was boiled in 1 L of water at 100°C for 2 hours, evaporated under a pressure of 98 kPa using an electric extractor (COSMOS-660), and the resulting mixture was filtered using a 53 μm filter. The filtered extract solution was dried to obtain 14.1 g of powder sample, which was mixed in distilled water at room temperature for 2 minutes to prepare a lily bulbus extract concentrate.

[0069] 2. Experimental cells and experimental animals

[0070] NS-SV-AC cells were used as experimental cells. NS-SV-AC cell lines were cultured in an animal cell culture medium supplemented with 10% fetal bovine serum (FBS), 100 U / mL penicillin, and 100 μg / mL streptomycin in a 5% CO2 incubator at 37˚C.

[0071] Twenty weeks of NOD / SCID mice were used as the Sjögren's syndrome mouse model, and BALB / c mice were used as the control group. The mice were managed in a pathogen-free environment on a 12-hour day / night cycle. The mouse models were randomly divided into five groups: a normal group, a control group, and three groups administered different doses of lily extract orally (100, 500, and 1000 mg / kg). The experimental animals were administered lily extract for five days a week for four weeks, and their body weight was measured weekly to monitor the dosage and health status.

[0073] 3. Evaluation of cell viability through MTT analysis

[0074] To evaluate cell viability, an MTT assay was performed using mitochondrial dehydrogenase. Acinar cells were placed in a 96-well plate at a density of 5 × 10⁶ 5The cells were cultured at a density of cells / mL, and treated with 1, 5, 10, 50, or 100 μg / mL of lily extract and 2 μM / mL of 5-aza-2'-deoxycytidine and cultured for 48 hours. The culture medium was replaced, and the cells were cultured with 0.5 mg / mL of MTT solution for 4 hours. Afterward, the supernatant was removed, and the formazan blue formed within the cells was dissolved with dimethyl sulfoxide and measured using an ELISA plate reader (MRX).

[0076] 4. Measurement of salivary secretion rate

[0077] Salivary secretion rate was measured in control acinar cells and cells treated with 2 μM / mL of 5-aza-2'-deoxycytidine for 48 hours. Acinar cells were cultured in a 6-well medium chamber, and the apical and lateral bottom media were replaced with hyperosmotic and isosmotic media, respectively. After 4 hours, the amount of saliva collected from the apical surface was measured to calculate the salivary secretion rate.

[0078] For in vivo experiments, experimental mice were anesthetized by administering 1.3 g / kg of urethane intraperitoneally. Saliva was collected from the floor of the mouth for about 10 minutes using a capillary paper plug, and the weight was measured before and after collection. The amount of saliva was standardized by time (10 minutes) and body weight (1 g).

[0080] 5. Protein extraction and Western blot analysis

[0081] To extract total protein, NS-SV-AC cells and the salivary glands of NOD / SCID mice were treated with lysis buffer at 4°C for 1 hour. Insoluble substances were removed after centrifugation at 13,000 × g for 20 minutes at 4°C using a centrifuge. Subsequently, equal amounts of protein were separated by electrophoresis using 10% SDS-PAGE at 120 V for 2 hours, transferred to a membrane, and blocked for 1 hour by adding 0.5% polysorbate 20 (Tween-20) to TBS (Tris-buffered saline) containing 5% skim milk. The membrane was then treated to react with rabbit-derived anti-AQP5, anti-M3R, and anti-β-tubulin.

[0083] 6. Immunofluorescence

[0084] Cells treated with 5-aza-2'-deoxycytidine were plated onto glass slides and treated with lily extract for 48 hours. The cells were fixed with 2% paraformaldehyde and treated with anti-AQP5 antibody at room temperature for 4 hours. Cyanine dye (Cy3) conjugated immunoglobulin G (IgG) antibody was used as the secondary antibody. Immunostained cells were treated with mounting medium containing DAPI and observed using an immunofluorescence microscope.

[0086] 7. Autoantibody profiling using ELISA

[0087] IgG detection was performed using Mouse Anti-SSA / Ro and Anti-SSB / La ELISA kits. All serum samples were diluted 1:50 for use.

[0089] 8. Measurement of inflammatory cytokines using ELISA

[0090] TNF-α and IFN-γIL-6 were analyzed in the serum of a NOD / SCID mouse model using a mouse TNF-α and IFN-γIL-6 ELISA kit.

[0092] 9. Histopathological observation of salivary glands

[0093] Salivary glands from experimental mice were collected, fixed using a 4% paraformaldehyde solution, and immersed in an OCT (optimal cutting temperature compound). The fixed salivary gland sections were cut into 5 μm thick slices. Hematoxylin staining was used to investigate histological changes in the salivary glands.

[0095] 10. Statistical analysis

[0096] Statistical analysis was performed using GraphPrism 4.0.3 software and the statistical software SPSS. Data were expressed as mean ± standard deviation or mean ± standard error. One-way ANOVA was used to compare mean differences between groups, followed by post-hoc analysis using Dunnett's test. A p-value less than 0.05 was considered statistically significant.

[0098] <Example>

[0099] 1. Cell viability evaluation (in vitro)

[0100] The effect of LB on the viability of acinar cells was measured using an MTT assay. Prior to the experiment, growth-controlled acinar cells were placed in starvation medium for 24 hours and then treated with LB and 2 μM / mL of 5-Aza and cultured for 48 hours. The viability of cells treated with 5-Aza and LB (1, 5, 10, 50, 100 μg / mL) was significantly increased compared to LB-untreated cells (Figure 1).

[0102] 2. salivary secretion-promoting effect of lily extract

[0103] The effect of lily extract on the secretion rate of human salivary gland acinar cells (NS-SV-AC) was evaluated. Cells treated with 2 μM / mL 5-Aza showed a decrease in salivary secretion rate compared to untreated normal acinar cells. However, this was not statistically significant. In contrast, cells treated with 10 μg / mL LB after 5-Aza treatment showed a significantly increased salivary secretion rate compared to cells treated with 5-Aza alone (Fig. 2).

[0105] 3. Changes in Aquaporin-5 (AQP5) Protein Expression Levels

[0106] Western blotting and immunofluorescence were performed to confirm the effect of lily extract on the expression of AQP5 protein. The results showed that the expression of AQP5 protein in cells treated with 5-Aza alone was significantly decreased compared to untreated normal cells. However, in cells treated with 2 μM / mL 5-Aza, AQP5 expression was significantly increased when treated with 1, 10, and 100 μg / mL LB compared to cells treated with 5-Aza alone (Fig. 3).

[0107] In addition, immunofluorescence analysis of AQP5 protein in acinar cells confirmed that the results were consistent with the Western blotting results. AQP5 protein expression in cells treated with 5-Aza alone (Figs. 4C, 4D) was lower than in untreated normal cells (Figs. 4A, 4B). However, when 2 μM / mL 5-Aza-treated cells were treated with 100 μg / mL LB, AQP5 expression was found to be higher than in cells treated with 5-Aza alone (Figs. 4E, 4F).

[0109] 4. Increased saliva secretion

[0110] Experiments were conducted to determine whether lily extract exhibited an in vivo effect of increasing salivary gland secretion in NOD / SCID mice. As a result, salivary secretion in the control group of NOD / SCID mice was significantly lower than that of the normal BALB / c mouse group; however, when LB was administered at various concentrations of 100, 500, and 1000 mg / kg to NOD / SCID mice, it was confirmed that salivary gland secretion significantly increased compared to the control group (Fig. 5).

[0112] 5. Increase in AQP5 and M3R proteins

[0113] Salivary secretion is associated with membrane channel proteins and aquaporin mechanisms. AQP5 is a water transport channel protein present in acinar cells, and the M3 muscarinic acetylcholine receptor (M3R) is a protein with high expression levels in pancreatic B cells and is a major receptor that promotes salivary secretion in acinar cells. Therefore, Western blotting was performed to determine whether lily extract affects the expression levels of AQP5 and M3R proteins in NOD / SCID mice. As a result, it was confirmed that the expression level of AQP5 protein in control NOD / SCID mice was 69.0%, which was significantly reduced compared to normal mice (Figs. 6A, 6B). However, in the group of NOD / SCID mice treated with 1000 mg / kg of lily extract, the expression level of AQP5 was significantly higher compared to the control group (Fig. 6B). In addition, the expression level of M3R protein in the control group of NOD / SCID mice was 73.0%, which was significantly lower than that of the normal group (Figs. 6A, 6C), but it was confirmed that the expression level of M3R protein in the groups treated with 500 and 1000 mg / kg of lily extract in NOD / SCID mice was significantly increased compared to the control group (Fig. 6C).

[0115] 6. Reduction in the production of anti-SSA / Ro and anti-SSB / La autoantibodies

[0116] Anti-SSA / Ro and anti-SSB / La autoantibodies are known as autoimmune biomarkers associated with salivary and lacrimal gland damage caused by severe lymphocyte infiltration. Anti-SSA / Ro and anti-SSB / La are detected in approximately 60-70% of patients with primary Sjögren's syndrome. Accordingly, an enzyme-linked immunosorbent assay (ELISA) was performed to determine whether lily extract has the effect of reducing the production of the autoantibodies anti-SSA / Ro and anti-SSB / La in the serum of NOD / SCID mice.

[0117] In the NOD / SCID control group, the production of anti-SSA / Ro and anti-SSB / La antibodies was higher than in the normal group. However, in NOD / SCID mice treated with 100, 500, and 1000 mg / kg of lily extract, it was confirmed that the production of anti-SSA / Ro and anti-SSB / La antibodies decreased compared to the control group (Fig. 7).

[0119] 7. Inflammatory cytokines ( Reduction of TNF-α, IFN-γIL-6)

[0120] The balance between T-helper 1 (Th1) and T-helper 2 (Th2) cells plays a crucial role in autoimmune diseases. IFN-γ, an inflammatory cytokine secreted by Th1 cells, is known to be overexpressed in patients with Sjögren's syndrome, while TNF-α and IL-6 activate B cells and induce inflammatory responses; in particular, IL-6 is associated with B cell hyperactivation. To evaluate the inhibitory effect of LB treatment on the inflammatory response in NOD / SCID mice, TNF-α, IFN-γ, and IL-6 were analyzed using ELISA. As a result, the level of TNF-α in control NOD / SCID mice was 116.6 ± 19.0 pg / mL, which was significantly higher compared to the normal mouse group (p<0.001). However, it was confirmed that TNF-α levels were significantly reduced in the groups treated with 100 and 500 mg / kg of lily extract compared to the control group (Fig. 8A).

[0121] IFN-γ levels were significantly increased to 75.7 ± 20.3 pg / mL in the control group compared to the normal mouse group (p<0.01), and IFN-γ levels in the lily extract treatment groups of 100, 500, and 1000 mg / kg showed a statistically significant decrease compared to the control group (Fig. 8B).

[0122] IL-6 levels were significantly increased in the control group to 203.7±24.6 pg / mL compared to the normal mouse group (p<0.001), but IL-6 levels in the groups administered 100 and 500 mg / kg of lily extract were significantly lower than those in the control group (Fig. 8C).

[0124] 8. Mouse salivary gland tissue analysis

[0125] Hematoxylin and eosin staining were used to investigate the effects of lily extract treatment on morphological and histological changes in salivary glands. In the salivary glands of NOD / SCID mice, lymphocyte infiltration and inflammatory lesions were observed compared to the control group (Figs. 9A, 9B). However, in the groups treated with 100, 500, and 1000 mg / kg of lily extract, cell damage through infiltration and inflammation was improved compared to the control group (Figs. 9C, 9D, 9E).

[0127] In summary, lily extract promoted the proliferation of salivary gland cells, protected cells from 5-Aza-induced cytotoxicity, and increased salivary secretion rate and the expression of AQP5 protein. In addition, NOD / SCID mice treated with lily extract showed reduced production of the autoantibodies anti-SSA / Ro and anti-SSB / La, and suppressed the secretion of inflammatory cytokines TNF-α and IFN-γIL-6, thereby recovering salivary gland tissue damage caused by inflammation at the tissue level. Therefore, through the above examples and experimental examples, it was confirmed that the administration of lily extract for 4 weeks has a potential effect on the treatment of Sjögren's syndrome.

Claims

Claim 1 A pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome comprising lily extract as an active ingredient, wherein the composition increases salivary secretion by increasing the expression of Aquaporin-5 (AQP5) and muscarinic acetylcholine receptor (M3R). Claim 2 delete Claim 3 A pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome according to claim 1, characterized in that the extract reduces the secretion of inflammatory cytokines TNF-α, IFN-γ, or IL-6. Claim 4 A pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome according to claim 1, characterized in that the extract reduces the production of autoantibodies anti-SSA / Ro and anti-SSB / La. Claim 5 delete Claim 6 A method for preparing a pharmaceutical composition for the prevention, improvement, or treatment of Sjögren's syndrome, comprising: a step of drying lilies; a step of mixing distilled water with the dried lilies in a weight ratio of 1:20 and extracting at 90 to 110°C for 100 to 140 minutes; a step of concentrating the extracted lily extract under reduced pressure and then filtering; and a step of freeze-drying the filtered extract; wherein the composition increases salivary secretion by increasing the expression of Aquaporin-5 (AQP5) and muscarinic acetylcholine receptor (M3R). Claim 7 A food composition for preventing or improving Sjögren's syndrome comprising lily extract as an active ingredient, wherein the composition increases saliva secretion by increasing the expression of Aquaporin-5 (AQP5) and muscarinic acetylcholine receptor (M3R). Claim 8 delete Claim 9 A food composition for preventing or improving Sjögren's syndrome according to claim 7, characterized in that the extract reduces the secretion of inflammatory cytokines TNF-α, IFN-γ, or IL-6. Claim 10 A food composition for preventing or improving Sjögren's syndrome according to claim 7, wherein the extract is characterized by reducing the production of autoantibodies anti-SSA / Ro and anti-SSB / La. Claim 11 delete Claim 12 A method for preparing a food composition for preventing or improving Sjögren's syndrome, comprising: a step of drying lilies; a step of mixing distilled water with the dried lilies in a weight ratio of 1:20 and extracting at 90 to 110°C for 100 to 140 minutes; a step of concentrating the extracted lily extract under reduced pressure and then filtering; and a step of freeze-drying the filtered extract; wherein the composition increases saliva secretion by increasing the expression of Aquaporin-5 (AQP5) and muscarinic acetylcholine receptor (M3R).

Citation Information

Patent Citations

  • A pharmaceutical composition comprising extract of lilium lancifolium for prevention and treatment of inflammatory diseases and asthma

    KR1020100137223A